Stay updated on OptiPOM: Alternate Day Pomalidomide in Refractory MM Clinical Trial
Sign up to get notified when there's something new on the OptiPOM: Alternate Day Pomalidomide in Refractory MM Clinical Trial page.

Latest updates to the OptiPOM: Alternate Day Pomalidomide in Refractory MM Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe latest history shows a new entry Revision: v3.4.2 was added to the record history. The visible notice about government funding lapse was removed and the previous Revision: v3.4.1 entry was deleted.SummaryDifference0.7%

- Check21 days agoChange DetectedAdded a general site status notice regarding government funding lapse and Clinical Center operations, and recorded the release note 'Revision: v3.4.1'; removed the previous release note 'Revision: v3.4.0'.SummaryDifference0.7%

- Check28 days agoChange DetectedUI updates include a Show glossary toggle and color-coded change highlights on the history table (green for additions, red for deletions). The record history notes have been updated to Revision: v3.4.0, replacing the previous v3.3.4.SummaryDifference1.0%

- Check42 days agoChange DetectedRevision v3.3.4 was added and v3.3.3 removed in the history. This is a minor platform version update and does not alter trial data or content.SummaryDifference0.1%

- Check64 days agoChange DetectedAdded Revision: v3.3.3 to the page footer and removed the HHS Vulnerability Disclosure and Revision: v3.3.2 from the footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check85 days agoChange DetectedThe Record History now shows a new revision entry: v3.3.2 has been added, replacing the previous v3.3.1; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to OptiPOM: Alternate Day Pomalidomide in Refractory MM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the OptiPOM: Alternate Day Pomalidomide in Refractory MM Clinical Trial page.